BioMedNewsBreaks

ThursdayDec 09, 2021 2:27 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article…

Continue Reading

ThursdayDec 09, 2021 8:30 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Establishment of Regulatory Advisory Board, Strategic Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at the School of Pharmacy and the School of Medicine at the University of Maryland. Dr. Melnyk is an expert in manufacturing and regulatory requirements for pharmaceutical and medical device development. She is the senior regulatory…

Continue Reading

WednesdayDec 08, 2021 3:48 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Medical Device Certification for IoT-Powered Dry Herb Inhaler, Software

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received ISO 13485:2016/MDSAP and EN ISO 13485:2016 certification for its proprietary Internet of Things (“IoT”)-powered dry herb inhaler (the “RYAH Smart Inhaler”) and software application associated with the device. According to the update, the certification is a regulatory requirement and an international standard that outlines the requirements for a quality management system specific to the medical devices industry. “This is a monumental achievement for RYAH Group Inc. and its subsidiary, RYAH Medtech Inc., as we continue to reimagine plant-based medicine delivery solutions for doctors, clinics and their…

Continue Reading

WednesdayDec 08, 2021 2:46 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Delivering Evidence-Based DTx, Research Centered Around Psychedelics

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently released an operational update regarding the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology. The update detailed the company’s progress and plans for the immediate future. “As a member of the Digital Therapeutics Alliance, MINDCURE delivers digital therapeutics (‘DTx’) that are evidence-based interventions driven by high-quality software to prevent, manage and treat medical disorders,” reads a recent article. A leader in advanced proprietary technology and research centered around psychedelics, MINDCURE is currently advancing multiple programs and products…

Continue Reading

WednesdayDec 08, 2021 2:37 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. Tryp filed an IND with the U.S. Food and Drug Administration in September for treating overeating disorders in Florida and filed its second IND application earlier in November for fibromyalgia testing in Michigan. The FDA asked the company to change the scope of its eating disorders trial so that the initial Florida investigation can focus on patients with binge eating…

Continue Reading

WednesdayDec 08, 2021 10:35 am

BioMedNewsBreaks – Sixth Wave Innovations Inc.’s (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) AMIPs(TM) Technology to Be Used in Screening Against Omicron Variant

Sixth Wave (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) recently provided an update on its patent-pending Accelerated Molecularly Imprinted Polymer (“AMIPs(TM)”) technology relative to SARS-CoV-2 variants, in particular, B.1.1.529 (“Omicron”). As previously announced, the AMIPS platform was proven capable of detecting all variants of interest tested to date. According to the update, screening against the Omicron variant will commence as soon as virus samples are available at the La Ki Shing Institute of virology, SIXW's testing partner. The identification of yet another variant with suspected properties more transmissible and potentially dangerous than previous generations strongly indicates that COVID-19 will be around…

Continue Reading

TuesdayDec 07, 2021 12:56 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will sell the CGM under the brand MySugarWatch(R) and has developed a subscription-based diabetes coaching and management service to be provided alongside the CGM and device sensors primarily targeting those with type 2 diabetes. “This initial shipment of sugarBEAT CGM devices to our U.K. licensee allows…

Continue Reading

FridayDec 03, 2021 11:46 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Announces Participation in December 2021 Conferences

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, will be featured in several upcoming conferences. The company announced that president and CEO Kelsey Ramsden has been invited to present in four virtual conferences scheduled in December. Those conferences include the H.C. Wainwright's second annual Psychedelics Conference, the Psychedelics Now Virtual Conference, the #CanndoraConnect: Women in Psychedelics Conference, and the Life Sciences Investor Forum. The H.C. Wainwright Psychedelics Conference is scheduled for Dec. 6, 2021; Ramsden’s presentation will begin at 7 a.m. The Psychedelics Now Virtual Conference will be held…

Continue Reading

FridayDec 03, 2021 11:30 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…

Continue Reading

FridayDec 03, 2021 9:30 am

BioMedNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Lucid-MS Featured in InvestmentPitch Video, CEO to Present at H.C. Wainwright Psychedelics Virtual Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on over a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. FSD Pharma has released a video…

Continue Reading